Sai Parenteral's Initial Public Offering: A Guide to Key Aspects and IPO Details

Sai Parenteral's ₹409 Crore IPO Opens for Subscription Tomorrow

Key Highlights:

• ₹409 crore initial public offering (IPO) of Sai Parenteral's opens for subscription on March 24, 2026, and closes on March 27, 2026.
• The company has fixed a price band of ₹372 to ₹392 per share, placing the issue in a competitive valuation bracket within the pharma space.

Issue Structure and Objectives:

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

• The IPO is a book-built issue aggregating to ₹408.79 crore, comprising a fresh issue of 0.73 crore shares worth ₹285.00 crore and an offer for sale (OFS) of 0.32 crore shares amounting to ₹123.79 crore.
• The company plans to utilise the net proceeds towards multiple strategic and operational needs, including:
  • ₹110.80 crore for capacity expansion and upgradation of manufacturing facilities
  • ₹18.02 crore for establishing a new R&D centre
  • ₹14.30 crore for repayment or prepayment of borrowings
  • ₹33.00 crore for working capital requirements
  • ₹35.64 crore for investment in its wholly owned subsidiary in Singapore to support the proposed acquisition of Noumed Pharmaceuticals Pty Limited in Australia

Listing and Reservation Breakup:

• The company is likely to list on both the NSE and BSE with a tentative listing date of April 2, 2026.
• From an allocation standpoint, not more than 50% of the net offer is reserved for Qualified Institutional Buyers (QIBs), while retail investors will get not less than 35%, and Non-Institutional Investors (NIIs) will be allocated not less than 15% of the issue.

Book Running Lead Managers and Registrar:

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

• The IPO is being managed by Arihant Capital Markets Ltd., which is acting as the book running lead manager.
• Bigshare Services Pvt. Ltd. has been appointed as the registrar to the issue.

Peers and Company Overview:

• Sai Parenteral's operates in a competitive space alongside companies such as Sai Life Sciences, Innova Captab, Senores Pharma, and Gland Pharma.
• Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with capabilities across research, development, and manufacturing.

Financials:

• The company reported a net profit of ₹7.76 crore on revenue of ₹89.43 crore for the six months ended September 30, 2025.
• For FY25, Sai Parenteral's posted a net profit of ₹14.43 crore with revenue of ₹163.74 crore.
• At the upper price band, the company commands a market capitalisation of over ₹1,730 crore.